# Innospec Inc.: overview

IOSP · Nasdaq · CIK 1054905 · [Materials](/sectors/materials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/iosp.md) · [Financials](/companies/iosp/financials.md) · [Filings](/companies/iosp/filings.md) · [Insiders](/companies/iosp/insiders.md)

Latest reported revenue: [$491.4m](/filings/0001193125-26-334178.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 5, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-334178).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [443](/filings/0001193125-25-266077.md) | [467 d](/filings/0001193125-26-056502.md) | [441](/filings/0001193125-26-213510.md) | [440](/filings/0001193125-26-334178.md) | [442](/filings/0001193125-25-266077.md) | [456 d](/filings/0001193125-26-056502.md) | [453](/filings/0001193125-26-213510.md) | [491](/filings/0001193125-26-334178.md) |
| Gross margin | % | [28.0%](/filings/0001193125-25-266077.md) | [29.2% d](/filings/0001193125-26-056502.md) | [28.4%](/filings/0001193125-26-213510.md) | [28.0%](/filings/0001193125-26-334178.md) | [26.4%](/filings/0001193125-25-266077.md) | [28.0% d](/filings/0001193125-26-056502.md) | [27.3%](/filings/0001193125-26-213510.md) | [28.1%](/filings/0001193125-26-334178.md) |
| Operating margin | % | [10.3%](/filings/0001193125-25-266077.md) | [8.8% d](/filings/0001193125-26-056502.md) | [9.6%](/filings/0001193125-26-213510.md) | [7.8%](/filings/0001193125-26-334178.md) | [1.3%](/filings/0001193125-25-266077.md) | [10.3% d](/filings/0001193125-26-056502.md) | [8.1%](/filings/0001193125-26-213510.md) | [8.1%](/filings/0001193125-26-334178.md) |
| Net margin | % | [7.5%](/filings/0001193125-25-266077.md) | [(15.1%) d](/filings/0001193125-26-056502.md) | [7.4%](/filings/0001193125-26-213510.md) | [5.3%](/filings/0001193125-26-334178.md) | [2.9%](/filings/0001193125-25-266077.md) | [10.4% d](/filings/0001193125-26-056502.md) | [6.7%](/filings/0001193125-26-213510.md) | [6.3%](/filings/0001193125-26-334178.md) |
| Diluted EPS | $ per share | [1.33](/filings/0001193125-25-266077.md) | not reported | [1.31](/filings/0001193125-26-213510.md) | [0.94](/filings/0001193125-26-334178.md) | [0.52](/filings/0001193125-25-266077.md) | not reported | [1.22](/filings/0001193125-26-213510.md) | [1.25](/filings/0001193125-26-334178.md) |
| Free cash flow | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:ProfitLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,483](/filings/0000950170-24-014960.md) | [1,964](/filings/0000950170-25-022803.md) | [1,949](/filings/0001193125-26-056502.md) | [1,845](/filings/0001193125-26-056502.md) | [1,778](/filings/0001193125-26-056502.md) |
| Gross margin | % | [29.3%](/filings/0000950170-24-014960.md) | [29.9%](/filings/0000950170-25-022803.md) | [30.3%](/filings/0001193125-26-056502.md) | [29.4%](/filings/0001193125-26-056502.md) | [27.7%](/filings/0001193125-26-056502.md) |
| Operating margin | % | [8.9%](/filings/0000950170-24-014960.md) | [9.5%](/filings/0000950170-25-022803.md) | [8.3%](/filings/0001193125-26-056502.md) | [9.6%](/filings/0001193125-26-056502.md) | [7.3%](/filings/0001193125-26-056502.md) |
| Net margin | % | [6.3%](/filings/0000950170-24-014960.md) | [6.8%](/filings/0000950170-25-022803.md) | [7.1%](/filings/0001193125-26-056502.md) | [1.9%](/filings/0001193125-26-056502.md) | [6.6%](/filings/0001193125-26-056502.md) |
| Diluted EPS | $ per share | [3.75](/filings/0000950170-24-014960.md) | [5.32](/filings/0000950170-25-022803.md) | [5.56](/filings/0001193125-26-056502.md) | [1.42](/filings/0001193125-26-056502.md) | [4.67](/filings/0001193125-26-056502.md) |
| Free cash flow | $m | not reported | not reported | not reported | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:ProfitLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/iosp/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $356.6m | 4,381,323 |  | Added +502,348 |
| [Allspring Global Investments Holdings, LLC](/funds/1890906.md) | 2026-06-30 | $154.7m | 1,892,471 |  | Reduced −423,471 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $153.4m | 1,884,244 |  | Added +24,153 |
| [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $106.2m | 1,305,038 |  | Added +62,949 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $90.2m | 1,108,107 |  | Reduced −6,491 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $81.1m | 996,027 |  | Added +31,692 |
| [Nuveen, LLC](/funds/1871926.md) | 2026-06-30 | $61.5m | 755,723 |  | Added +112,475 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $54.3m | 666,589 |  | Added +35,997 |
| [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $53.9m | 662,210 |  | Added +170,199 |
| [VICTORY CAPITAL MANAGEMENT INC](/funds/1040188.md) | 2026-06-30 | $53.7m | 660,110 |  | Reduced −204,884 |

## Recent filings

[All 1,184 filings](/companies/iosp/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-05 | 14:32 ET | [10-Q](/filings/0001193125-26-334178.md) | Quarterly report, period 2026-06-30 | 0001193125-26-334178 |
| 2026-08-05 | 10:03 ET | [8-K](/filings/0001193125-26-333724.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-333724 |
| 2026-06-04 | 20:31 ET | [8-K](/filings/0001193125-26-257531.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-257531 |
| 2026-05-13 | 10:00 ET | [8-K](/filings/0001193125-26-220407.md) | 5.07 Shareholder vote results | 0001193125-26-220407 |
| 2026-05-08 | 13:34 ET | [10-Q](/filings/0001193125-26-213510.md) | Quarterly report, period 2026-03-31 | 0001193125-26-213510 |
| 2026-05-08 | 10:01 ET | [8-K](/filings/0001193125-26-213160.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-213160 |
| 2026-03-26 | 13:01 ET | [DEF 14A](/filings/0001174947-26-000427.md) | Proxy statement, period 2026-05-08 | 0001174947-26-000427 |
| 2026-02-18 | 17:12 ET | [10-K](/filings/0001193125-26-056502.md) | Annual report, period 2025-12-31 | 0001193125-26-056502 |
| 2026-02-18 | 11:03 ET | [8-K](/filings/0001193125-26-055921.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-055921 |
| 2025-11-05 | 15:23 ET | [10-Q](/filings/0001193125-25-266077.md) | Quarterly report, period 2025-09-30 | 0001193125-25-266077 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-056502.md), filed Feb 18, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/e30a586f-1034-4a97-876b-d17c17e831a1)

## About the filer

- CIK: 1054905
- Tickers: IOSP
- Exchange: Nasdaq
- SIC code: 2800 Chemicals & Allied Products
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:31 ET. No prices; not investment advice.